Image by Racool_studio on Freepik
Researchers from Swansea University have discovered that a medication frequently used to treat type 2 diabetes may also be effective in treating autoimmune diseases.
Researchers at the University’s Faculty of Medicine, Health, and Life Sciences have discovered that the medication canagliflozin, also known as Invokana, may be used to treat autoimmune diseases like systemic lupus erythematosus and rheumatoid arthritis because it targets T-cells, a vital immune system component. Canagliflozin is a medication that lowers blood sugar levels in persons with type 2 diabetes, but researchers have discovered that it also has an unanticipated effect on the immune system.
Targeting T-cell metabolism in autoimmune disease has been shown to have therapeutic advantages. T-cells are a type of white blood cell that aids in the body’s defense against infections and sickness, but they have been seen to assault healthy tissues in autoimmune diseases.
Canagliflozin dampens T-cell activation, according to a recent study that was published in the journal Cell Metabolism. This finding raises the possibility that the medication could be used to treat T-cell-driven autoimmunity.
Dr. Nick Jones, senior author who led the study said, “Our findings are significant as they provide the foundation for the clinical development of canagliflozin for the treatment of certain autoimmune diseases. As the drug is already widely used and has a known safety profile in humans, it could potentially reach clinic quicker than any new drugs developed and bring valuable benefits more swiftly to patients with autoimmune disorders.”
Ben Jenkins, first author and postdoctoral researcher at Swansea said, “Identifying new roles for drugs that are currently being used in other disease settings is an exciting area of research. Given that our research primarily targets the metabolism of immune cells, we hope that the potential therapeutic benefits of our findings are applicable to a wide range of conditions.”
Canagliflozin may one day be tested in a clinical setting for the treatment of specific autoimmune diseases, according to the researchers.
more recommended stories
Phage Therapy Study Reveals RNA-Based Infection ControlKey Takeaways (Quick Summary) Researchers uncovered.
Pelvic Floor Disorders: Treatable Yet Often IgnoredKey Takeaways (Quick Summary) Pelvic floor.
Urine-Based microRNA Aging Clock Predicts Biological AgeKey Takeaways (Quick Summary) Researchers developed.
Circadian Control of Neutrophils in Myocardial InfarctionKey Takeaways for HCPs Neutrophil activity.
E-Cigarette Use and Heart Attack Risk in Former SmokersKey Takeaways for Clinicians and Nurses.
36-Week Pre-eclampsia Screening May Reduce Term RiskA New Preventive Strategy for Term.
Cardiovascular Risk and Sudden Cardiac Death in DiabetesRising Sudden Cardiac Death (SCD) Risk.
Poor Kidney Function and Alzheimer’s Biomarkers ExplainedPoor kidney function may influence levels.
Walking Speed Before Hip Replacement Predicts RecoveryNew Evidence Points to a Simple,.
Neuroblastoma Drug Combo Extends Survival in ModelsA Promising Shift in High-Risk Neuroblastoma.
Leave a Comment